Brief: Imunon Reports Strong Enrollment Momentum In Phase 3 Ovation 3 Trial Of Imnn-001 In Advanced Ovarian Cancer
30/07/2026 14:01
BRIEF-Imunon Reports Strong Enrollment Momentum In Phase 3 Ovation 3 Trial Of Imnn-001 In Advanced Ovarian Cancer July 30 (Reuters) - Imunon Inc IMNN.O:
IMUNON REPORTS STRONG ENROLLMENT MOMENTUM IN PHASE 3 OVATION 3 TRIAL OF IMNN-001 IN ADVANCED OVARIAN CANCER
IMUNON - REPORTS ENROLLMENT RATE EXCEEDING FORECAST IN OVATION 3 TRIAL
IMUNON - PROJECTS ENROLLMENT COMPLETION IN Q2 2029 FOR OVATION 3 TRIAL
IMUNON - IMNN-001 DEMONSTRATES FAVORABLE SAFETY PROFILE WITH NO SERIOUS IMMUNE-RELATED ADVERSE EVENTS
Source text: ID:nGNX9jBnk6
Further company coverage: IMNN.O
((Reuters.Briefs@thomsonreuters.com;))